Developer docs
API playgroundTry for free, no card

Search company profiles

Centauri Therapeutics

Full company profile

uuid0000lpn

Namestring
Centauri Therapeutics
Legal namestring
Centauri Therapeutics Limited
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Centauri Therapeutics Limited is a UK-based clinical-stage biotechnology company founded in 2015 and headquartered at Alderley Park, Cheshire. The company develops immunotherapeutic candidates built on its proprietary Alphamer® platform, a class of synthetic antibody recruiting molecules (ARMs) that redirect naturally existing anti-alphaGal antibodies in the human body to target pathogens or cancer cells. Each Alphamer is modular, comprising a targeting moiety that recognizes the disease target, a proprietary stable linker, and an immunological effector moiety that displays sugar epitopes to recruit the host's pre-existing polyclonal antibody repertoire, producing a dual mechanism of direct pathogen inhibition plus immune activation.

The company's lead clinical candidate is CTX-187, developed under the ABX-01 programme, which targets multidrug-resistant Gram-negative bacterial infections, with an initial indication focused on lung infections in vulnerable and immune-compromised patients. CTX-187 entered Phase I first-in-human trials in early 2026 and received FDA Qualified Infectious Disease Product (QIDP) designation in March 2026, conferring eligibility for priority review and additional market exclusivity under the GAIN Act. Earlier pipeline work includes CTX-09, a bifunctional immunotherapy molecule for which pre-clinical proof-of-concept data was published in 2025. The underlying Alphamer platform is also patented for oncology applications, representing a latent pipeline branch.

Centauri operates as a pre-revenue company with a business model centered on out-licensing or co-development partnerships with major pharmaceutical companies for global commercialization following successful clinical development. The company has raised approximately £30 million in Series A funding (original £24M in January 2022, extended by £6M from the AMR Action Fund in February 2026) plus $12.3 million in cumulative non-dilutive support from CARB-X since 2019 and a £1 million grant from PACE in 2024. Core institutional investors include Boehringer Ingelheim Venture Fund, Evotec SE, Novo Holdings REPAIR Impact Fund, and the AMR Action Fund, all of which hold board representation.

Short descriptiontext

Centauri Therapeutics is a UK-based clinical-stage biotech developing Alphamer® antibody-recruiting immunotherapies, with lead candidate CTX-187 in Phase I trials for multidrug-resistant Gram-negative bacterial infections, pursuing future out-licensing partnerships with major pharmaceutical companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immunotherapy platform, antimicrobial resistance therapeutics, antibody recruiting molecules, clinical-stage biotechnology, infectious disease treatments
Industry2 codes
PRIMARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Antimicrobial Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue / Pipeline Development
TypeLicensing Royalties
Description

Centauri Therapeutics is a pre-revenue clinical-stage biotech company. The company is developing immunotherapeutic candidates (CTX-187 in ABX-01 programme) through clinical trials. Revenue generation is expected through out-licensing, co-development partnerships, or eventual product commercialization upon regulatory approval.

finsmes.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Centauri Therapeutics is a clinical-stage biotechnology company developing immunotherapeutic treatments through its proprietary Alphamer® platform technology. The platform uses synthetic Antibody Recruiting Molecules (ARMs) to redirect naturally existing polyclonal anti-alphaGal antibodies against pathogens or cancer cells, combining direct antibacterial activity with immune activation. The lead candidate CTX-187 targets multidrug-resistant Gram-negative bacterial infections and is currently in Phase I clinical trials, with planned out-licensing or co-development with major pharmaceutical companies for eventual commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • First pre-clinical proof-of-concept demonstrating endogenous antibody recruitment to address multi-drug resistant Gram-negative infections
Product overview1 text field

Centauri Therapeutics is an immunotherapy company with a proprietary Alphamer® platform technology applicable across infectious diseases and oncology. The company's current focus is on developing novel treatments for infectious diseases, particularly antimicrobial resistance. The core Alphamer® platform uses synthetic molecules to redirect naturally existing antibodies to treat life-threatening diseases. The lead clinical programme is ABX-01 with CTX-187 as the lead candidate targeting multidrug-resistant Gram-negative bacterial infections. Additional compounds including CTX-09 have demonstrated proof-of-concept activity. The platform also has potential applications in oncology with proof-of-concept data generated.

Product and service4 records
1Alphamer® Platform
CategoryImmunotherapy Technology Platform
Description

Proprietary immunotherapy technology platform that uses synthetic Antibody Recruiting Molecules (ARMs) to redirect pre-existing natural anti-alphaGal antibodies to treat life-threatening diseases. The platform comprises three modular components: targeting moiety, stable linker, and immunological effector moiety displaying sugar epitopes. Applicable across infectious diseases and oncology indications.

2ABX-01 Programme
CategoryClinical Development Programme
Description

Clinical development programme focused on broad-spectrum antimicrobial candidates targeting antibiotic-resistant Gram-negative bacteria. Lead compound is CTX-187, currently in Phase I clinical trials. Supported by CARB-X with $12.3M total funding since 2019.

3CTX-187
CategoryLead Clinical Candidate (Antimicrobial)
Description

Broad-spectrum antimicrobial immunotherapy candidate built on the Alphamer® platform, targeting multidrug-resistant Gram-negative bacteria. Combines immunotherapeutic effects with intrinsic antibacterial activity as a dual-mechanism therapy for Gram-negative bacterial infections including lung infections. Currently in Phase I clinical trials with FDA QIDP designation granted in March 2026.

4CTX-09
CategoryResearch Compound (Pre-clinical)
Description

Novel bifunctional immunotherapy molecule based on Alphamer® platform demonstrating direct, broad-spectrum antibacterial activity in vitro and in vivo with enhanced immune activation through anti-alphaGal antibody recruitment. Represents the first pre-clinical application of endogenous antibody recruitment to address multi-drug resistant Gram-negative infections.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swiss clinical-stage AMR biotech developing small-molecule therapeutics targeting drug-resistant infections, also backed by AMR Action Fund and CARB-X. Most directly comparable peer given shared investor base, AMR focus, and clinical-stage status.

TypeDirect peer
Description

AMR-focused biotech developing novel anti-infectives, with AMR Action Fund board representation. Comparable as a privately-held AMR developer with shared strategic backers.

TypeDirect peer
Description

AMR-focused biotech spun out of Evotec/GSK/University of Lyon consortium, with Antonio Felici (Centauri board member from Evotec) serving as board director. Highly comparable AMR pipeline and stage.

4Utility Therapeutics
TypeDirect peer
Description

AMR-focused biotech developing therapies for drug-resistant infections, backed by AMR Action Fund. Comparable size, stage, and AMR focus with shared lead investor.

TypeDirect peer
Description

AMR-focused biotech using AI/ML for antibiotic discovery targeting Gram-negative infections. Comparable target indication (MDR Gram-negative) and AMR strategic positioning.

TypeDirect peer
Description

UK-based clinical-stage anti-infective biotech (antifungal) with similar size, stage, and European base. Comparable as a small-cap European anti-infective developer addressing resistant pathogens.

TypeEmerging player
Description

CARB-X portfolio company developing novel antibiotics against MDR Gram-negative bacteria. Comparable target pathogen class and non-dilutive funding pathway.

TypeEmerging player
Description

Clinical-stage developer of phage-based therapies targeting MDR bacterial infections. Comparable AMR focus and clinical stage, but uses a different (phage) therapeutic modality.

TypeEmerging player
Description

Anti-infective company developing oral antibiotics for MDR Gram-negative infections. Comparable target indication but at a more advanced (commercial) stage with oral sulopenem.

TypeEmerging player
Description

Anti-infective company focused on serious bacterial infections including Gram-negative pathogens. Comparable AMR focus as a commercial-stage specialty anti-infective player.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Centauri Therapeutics

Antimicrobial Therapeuticscentauritherapeutics.com

Centauri Therapeutics is a UK-based clinical-stage biotech developing Alphamer® antibody-recruiting immunotherapies, with lead candidate CTX-187 in Phase I trials for multidrug-resistant Gram-negative bacterial infections, pursuing future out-licensing partnerships with major pharmaceutical companies.

What Centauri Therapeutics does

Centauri Therapeutics Limited is a UK-based clinical-stage biotechnology company founded in 2015 and headquartered at Alderley Park, Cheshire. The company develops immunotherapeutic candidates built on its proprietary Alphamer® platform, a class of synthetic antibody recruiting molecules (ARMs) that redirect naturally existing anti-alphaGal antibodies in the human body to target pathogens or cancer cells. Each Alphamer is modular, comprising a targeting moiety that recognizes the disease target, a proprietary stable linker, and an immunological effector moiety that displays sugar epitopes to recruit the host's pre-existing polyclonal antibody repertoire, producing a dual mechanism of direct pathogen inhibition plus immune activation.

The company's lead clinical candidate is CTX-187, developed under the ABX-01 programme, which targets multidrug-resistant Gram-negative bacterial infections, with an initial indication focused on lung infections in vulnerable and immune-compromised patients. CTX-187 entered Phase I first-in-human trials in early 2026 and received FDA Qualified Infectious Disease Product (QIDP) designation in March 2026, conferring eligibility for priority review and additional market exclusivity under the GAIN Act. Earlier pipeline work includes CTX-09, a bifunctional immunotherapy molecule for which pre-clinical proof-of-concept data was published in 2025. The underlying Alphamer platform is also patented for oncology applications, representing a latent pipeline branch.

Centauri operates as a pre-revenue company with a business model centered on out-licensing or co-development partnerships with major pharmaceutical companies for global commercialization following successful clinical development. The company has raised approximately £30 million in Series A funding (original £24M in January 2022, extended by £6M from the AMR Action Fund in February 2026) plus $12.3 million in cumulative non-dilutive support from CARB-X since 2019 and a £1 million grant from PACE in 2024. Core institutional investors include Boehringer Ingelheim Venture Fund, Evotec SE, Novo Holdings REPAIR Impact Fund, and the AMR Action Fund, all of which hold board representation.

Centauri Therapeutics firmographics

Firmographics
Name
Centauri Therapeutics
Legal name
Centauri Therapeutics Limited
Website
https://centauritherapeutics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Centauri Therapeutics is a UK-based clinical-stage biotech developing Alphamer® antibody-recruiting immunotherapies, with lead candidate CTX-187 in Phase I trials for multidrug-resistant Gram-negative bacterial infections, pursuing future out-licensing partnerships with major pharmaceutical companies.
Ownership category
akta.pro rank

Centauri Therapeutics industry classification

Industry
Product category
Antimicrobial Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Immunotherapy platform
  • Antimicrobial resistance therapeutics
  • Antibody recruiting molecules
  • Clinical-stage biotechnology
  • Infectious disease treatments

Where Centauri Therapeutics is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Centauri Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pre-revenue / Pipeline Development: Centauri Therapeutics is a pre-revenue clinical-stage biotech company. The company is developing immunotherapeutic candidates (CTX-187 in ABX-01 programme) through clinical trials. Revenue generation is expected through out-licensing, co-development partnerships, or eventual product commercialization upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Centauri Therapeutics product offering

Product offering

Core offering

Centauri Therapeutics is a clinical-stage biotechnology company developing immunotherapeutic treatments through its proprietary Alphamer® platform technology. The platform uses synthetic Antibody Recruiting Molecules (ARMs) to redirect naturally existing polyclonal anti-alphaGal antibodies against pathogens or cancer cells, combining direct antibacterial activity with immune activation. The lead candidate CTX-187 targets multidrug-resistant Gram-negative bacterial infections and is currently in Phase I clinical trials, with planned out-licensing or co-development with major pharmaceutical companies for eventual commercialization.

Product overview

Centauri Therapeutics is an immunotherapy company with a proprietary Alphamer® platform technology applicable across infectious diseases and oncology. The company's current focus is on developing novel treatments for infectious diseases, particularly antimicrobial resistance. The core Alphamer® platform uses synthetic molecules to redirect naturally existing antibodies to treat life-threatening diseases. The lead clinical programme is ABX-01 with CTX-187 as the lead candidate targeting multidrug-resistant Gram-negative bacterial infections. Additional compounds including CTX-09 have demonstrated proof-of-concept activity. The platform also has potential applications in oncology with proof-of-concept data generated.

Differentiator

Problem solved

Functional benefit

Products and services

  • Alphamer® Platform Proprietary immunotherapy technology platform that uses synthetic Antibody Recruiting Molecules (ARMs) to redirect pre-existing natural anti-alphaGal antibodies to treat life-threatening diseases. The platform comprises three modular components: targeting moiety, stable linker, and immunological effector moiety displaying sugar epitopes. Applicable across infectious diseases and oncology indications.
  • ABX-01 Programme Clinical development programme focused on broad-spectrum antimicrobial candidates targeting antibiotic-resistant Gram-negative bacteria. Lead compound is CTX-187, currently in Phase I clinical trials. Supported by CARB-X with $12.3M total funding since 2019.
  • CTX-187 Broad-spectrum antimicrobial immunotherapy candidate built on the Alphamer® platform, targeting multidrug-resistant Gram-negative bacteria. Combines immunotherapeutic effects with intrinsic antibacterial activity as a dual-mechanism therapy for Gram-negative bacterial infections including lung infections. Currently in Phase I clinical trials with FDA QIDP designation granted in March 2026.
  • CTX-09 Novel bifunctional immunotherapy molecule based on Alphamer® platform demonstrating direct, broad-spectrum antibacterial activity in vitro and in vivo with enhanced immune activation through anti-alphaGal antibody recruitment. Represents the first pre-clinical application of endogenous antibody recruitment to address multi-drug resistant Gram-negative infections.

Quantifiable outcome

  • First pre-clinical proof-of-concept demonstrating endogenous antibody recruitment to address multi-drug resistant Gram-negative infections

Companies that use Centauri Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Centauri Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Centauri Therapeutics partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Centauri Therapeutics competitors and assessment

Company assessment

Direct peers

  • BioVersys AG: Swiss clinical-stage AMR biotech developing small-molecule therapeutics targeting drug-resistant infections, also backed by AMR Action Fund and CARB-X. Most directly comparable peer given shared investor base, AMR focus, and clinical-stage status.
  • Elion Therapeutics: AMR-focused biotech developing novel anti-infectives, with AMR Action Fund board representation. Comparable as a privately-held AMR developer with shared strategic backers.
  • AUROBAC Therapeutics: AMR-focused biotech spun out of Evotec/GSK/University of Lyon consortium, with Antonio Felici (Centauri board member from Evotec) serving as board director. Highly comparable AMR pipeline and stage.
  • Utility Therapeutics: AMR-focused biotech developing therapies for drug-resistant infections, backed by AMR Action Fund. Comparable size, stage, and AMR focus with shared lead investor.
  • Phare Bio: AMR-focused biotech using AI/ML for antibiotic discovery targeting Gram-negative infections. Comparable target indication (MDR Gram-negative) and AMR strategic positioning.
  • F2G Ltd: UK-based clinical-stage anti-infective biotech (antifungal) with similar size, stage, and European base. Comparable as a small-cap European anti-infective developer addressing resistant pathogens.

Emerging players

  • VenatoRx Pharmaceuticals: CARB-X portfolio company developing novel antibiotics against MDR Gram-negative bacteria. Comparable target pathogen class and non-dilutive funding pathway.
  • Adaptive Phage Therapeutics: Clinical-stage developer of phage-based therapies targeting MDR bacterial infections. Comparable AMR focus and clinical stage, but uses a different (phage) therapeutic modality.
  • Iterum Therapeutics: Anti-infective company developing oral antibiotics for MDR Gram-negative infections. Comparable target indication but at a more advanced (commercial) stage with oral sulopenem.
  • Melinta Therapeutics: Anti-infective company focused on serious bacterial infections including Gram-negative pathogens. Comparable AMR focus as a commercial-stage specialty anti-infective player.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Centauri Therapeutics social profiles

Digital presence

Centauri Therapeutics compliance and trust

Trust signal

Compliance2 records

Centauri Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Centauri Therapeutics leadership team

Management profile

Number of profiles

Profiles13 records

Centauri Therapeutics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Centauri Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centauri Therapeutics

What does Centauri Therapeutics do?

Centauri Therapeutics is a clinical-stage biotechnology company developing immunotherapeutic treatments through its proprietary Alphamer® platform technology. The platform uses synthetic Antibody Recruiting Molecules (ARMs) to redirect naturally existing polyclonal anti-alphaGal antibodies against pathogens or cancer cells, combining direct antibacterial activity with immune activation. The lead candidate CTX-187 targets multidrug-resistant Gram-negative bacterial infections and is currently in Phase I clinical trials, with planned out-licensing or co-development with major pharmaceutical companies for eventual commercialization.

Is Centauri Therapeutics a public or private company?

Centauri Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Centauri Therapeutics founded?

Centauri Therapeutics was founded in 2015. It employs 11 to 50 people.

Where is Centauri Therapeutics based?

Centauri Therapeutics is headquartered in London, United Kingdom, in the Europe region.

How does Centauri Therapeutics make money?

One revenue line is on record: pre-revenue / Pipeline Development.

Who are Centauri Therapeutics's main competitors?

Direct peers on record are BioVersys AG, Elion Therapeutics, AUROBAC Therapeutics, Utility Therapeutics, Phare Bio and F2G Ltd. Emerging players are VenatoRx Pharmaceuticals, Adaptive Phage Therapeutics, Iterum Therapeutics and Melinta Therapeutics.

Does Centauri Therapeutics have an API?

No public API is recorded for Centauri Therapeutics.

What industry is Centauri Therapeutics in?

Centauri Therapeutics's product category is Antimicrobial Therapeutics. Its primary akta.pro industry code is HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FoundersTodayCentauri Therapeutics secures £6M Series A extension to advance antimicrobial immunotherapy candidateCentauri Therapeutics, a UK-based immunotherapy company, has secured a £6 million Series A extension led by the AMR Action Fund, bringing its total Series A financing to £30 million. The funding will support Phase I clinical studies for CTX-187, a broad-spectrum antimicrobial candidate targeting multidrug-resistant Gram-negative bacterial infections. As part of the investment, AMR Action Fund representative Henni-Karoliina Ropponen has joined Centauri's Board of Directors.InsidermediaCentauri Therapeutics extends Series A to £30m with investment from AMR Action FundCentauri Therapeutics, a Cheshire-based immunotherapy company, has secured £6m from the AMR Action Fund, extending its Series A round to £30m, to support Phase I clinical studies for CTX-187, its lead clinical candidate in the ABX-01 programme. The investment will fund first-in-human trials and preparation for Phase II studies, with Dr. Henni-Karoliina Ropponen from the AMR Action Fund appointed to Centauri's board. The funding reinforces the company's Alphamer platform as a transformative immunotherapeutic approach for addressing drug-resistant infections.Pulse 2.0Centauri Therapeutics: £6 Million Raised For Advancing Antimicrobial CandidateCentauri Therapeutics Limited has secured £6 million from AMR Action Fund, extending its Series A financing to £30 million, to support Phase I clinical studies for CTX-187, its lead broad-spectrum antimicrobial candidate targeting drug-resistant Gram-negative bacteria. The investment includes the appointment of Dr. Henni-Karoliina Ropponen from AMR Action Fund to Centauri's Board of Directors. CTX-187, built on Centauri's proprietary Alphamer platform, combines immunotherapeutic effects with intrinsic antibacterial activity as a dual-mechanism therapy.News-MedicalCentauri Therapeutics extends Series A to £30 M with £6 M investment from AMR Action Fund to support progression of lead clinical candidateCentauri Therapeutics Limited has secured £6 million from AMR Action Fund, extending its Series A round to £30 million total, to advance CTX-187 through Phase I clinical trials. CTX-187 is a broad-spectrum antimicrobial candidate built on Centauri's Alphamer platform, designed to treat multidrug-resistant Gram-negative bacteria. As part of the investment, Dr. Henni-Karoliina Ropponen from AMR Action Fund has been appointed to Centauri's Board of Directors.BioSpaceCentauri Therapeutics Extends Series A to £30M With £6M Investment From AMR Action Fund to Support Progression of Lead Clinical CandidateCentauri Therapeutics Limited secured £6M from AMR Action Fund, extending its Series A round to £30M, with the funding designated for Phase I clinical trials of CTX-187 targeting multidrug-resistant Gram-negative bacterial infections. Dr. Henni-Karoliina Ropponen from AMR Action Fund was appointed to Centauri Therapeutics' Board of Directors as part of the investment agreement. The investment provides Centauri a clear pathway to advance CTX-187 beyond Phase I trials toward Phase II development.SoapboxCentauri Therapeutics secures a £6m Series A extension from AMR Action Fund to target drug-resistant bacterial infections with immunotherapyCentauri Therapeutics has secured £6 million in additional funding from AMR Action Fund, bringing its Series A round to £30 million. The investment will support Phase I clinical trials for CTX-187, the lead candidate in the ABX-01 programme, designed as a broad-spectrum antimicrobial targeting multidrug-resistant Gram-negative bacteria. Dr. Henni-Karoliina Ropponen from AMR Action Fund has joined Centauri's Board of Directors as part of the deal.MorningstarCentauri Therapeutics Extends Series A to £30M With £6M Investment From AMR Action Fund to Support Progression of Lead Clinical CandidateCentauri Therapeutics has secured £6M from AMR Action Fund, extending its Series A round to £30M, to support Phase I clinical studies for CTX-187, its lead candidate targeting drug-resistant Gram-negative bacterial infections. The investment will fund first-in-human trials and preparation for Phase II studies, with Dr. Henni-Karoliina Ropponen from AMR Action Fund joining Centauri's Board of Directors. Centauri previously closed a £24M Series A round in January 2022 with backing from Boehringer Ingelheim Venture Fund, Evotec SE, and Novo Holdings REPAIR Impact Fund.FinSMEsCentauri Therapeutics Raises £6M in Series A Extension FundingCentauri Therapeutics, an immunotherapy company based in Alderley Park, UK, raised £6M in Series A extension funding led by AMR Action Fund, bringing total Series A funding to £30M. The company intends to use the proceeds to complete Phase I clinical studies for CTX-187, its lead clinical candidate in the ABX-01 programme targeting antibiotic-resistant Gram-negative bacteria, and to expand research activities in preparation for Phase II. The funding supports the advancement of the company's Alphamer technology platform, which uses synthetic molecules to redirect pre-existing antibodies against pathogens or cancer cells.Business Wire BlogCentauri Therapeutics Extends Series A to £30M With £6M Investment From AMR Action Fund to Support Progression of Lead Clinical CandidateCentauri Therapeutics Limited secured £6M in funding from AMR Action Fund, extending its Series A round to £30M, to advance CTX-187 through Phase I clinical trials for Gram-negative bacterial infections. The investment from the world's largest venture capital fund dedicated exclusively to antimicrobial therapeutics will support completion of Phase I studies and preparation for Phase II development. Dr. Henni-Karoliina Ropponen, Venture Associate at AMR Action Fund, has been appointed to Centauri's Board of Directors.